Clinical Trial

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

Study acronym: HERO
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-07.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-16
Trial Details
NCT Number NCT07118670
Lead Sponsor Edward Wood, MD
Collaborators: Greater Houston Retina Research
Conditions Proliferative Diabetic Retinopathy (PDR)
Enrollment 40 participants
Start Date 2025-12-08
Primary Completion 2028-02 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-18